Medical imaging software developer MIM Software has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for post-treatment dosimetry of yttrium-90 (Y-90) microspheres. MIM SurePlan LiverY90 provides tools for liver and tumor segmentation, deformable registration, and patient-specific dose calculation on Y-90 PET and Bremsstrahlung SPECT images after permanent Y-90 microsphere implant administration. {read more here}

Positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG-PET) both complemented and sometimes contradicted clinical assessment in large-vessel vasculitis (LVV) patients, and scan-identified disease activity in patients in clinical remission was associated with future relapse in a majority of patients, according to a study online in Arthritis & Rheumatology. {read more here}

HER2-positive breast-cancer patients are safely and effectively imaged with PET/CT after being infused with a solution based on the radiotracer pertuzumab, according to a study published online Nov. 16 in the Journal of Nuclear Medicine.  {read more here}

Positron emission tomography (PET)-based molecular imaging biomarkers may predict therapeutic response and survival in patients with metastatic castration-resistant prostate cancer (mCRPC), researchers say. {read more here}